Gilead Sciences To Acquire Arcellx For $7.8 Billion At $115 Share
Gilead Sciences agreed to acquire Arcellx for $7.8 billion, paying $115 per share in cash plus a $5-per-share contingent value right. The deal secures full control of anito-cel, a CAR-T multiple myeloma therapy, and aims to accelerate its commercialization timeline.
1. Acquisition Terms
Gilead Sciences agreed to acquire Arcellx for $7.8 billion, paying $115 per share in cash and offering an additional $5-per-share contingent value right tied to clinical milestones.
2. Strategic Rationale
The acquisition secures full control of anito-cel, a next-generation CAR-T therapy for multiple myeloma that has delivered promising clinical results, with the goal of accelerating its path to market.
3. Market Reaction and Analysis
Following the announcement, Arcellx shares rose toward their 52-week high while trading 2.5% below the 20-day SMA and 3.8% under the 100-day SMA; analysts set an average price target of $112.47 amid recent hold downgrades.